PDEX · Pro-Dex, Inc.

0001079973-26-000580

Summary

Q3 delivered revenue growth and robust net income expansion, driven by medical device demand and NRE project acceleration, though operating income moderated due to higher inventory reserves and cost absorption on scaling production.

Key takeaways

Revenue increased 14.6% to $19.9M from $17.4M, reflecting stronger medical device sales and NRE contributions.
Gross profit rose 5.8% to $6.1M from $5.8M, with gross margin at 30.7%.
Operating income declined 15.0% to $3.1M from $3.6M, pressured by elevated operating expenses.
Net income grew 20.2% to $3.9M from $3.3M, with diluted EPS up 22.4% to $1.20.

Full analysis

Operationally, the firm maintains a backlog of firm purchase orders, though it excludes potential revenue from existing contracts, signaling sustained but lumpy demand. Recent facility acquisition near Irvine headquarters bolsters capacity for expected revenue growth, including battery manufacturing and new products. Balance sheet expansions in key accounts align with this trajectory, positioning Pro-Dex to capitalize on medical sector opportunities while navigating cost dynamics.